MBC RESEARCH NEWS Getting to the Target: Antibody Drug Conjugates

May 2019

Getting to the Target: Antibody Drug Conjugates in Breast Cancer

Patients with metastatic HER2+ breast cancer gained a new treatment option when ado-trastuzumab emtansine (Kadcyla®) was approved in 2013. Kadcyla® is made up of the antibody, trastuzumab (Herceptin®) and the chemotherapy DM1. Herceptin® homes in on the HER2 protein on cancer cells and when it connects it releases the chemotherapy. This can reduce side effects that develop when chemotherapy attacks normal cells.

Kadcyla® remains the only antibody drug conjugate approved to treat metastatic breast cancer. Clinical trials are underway that are pursuing similar approaches and more antibody drug conjugates are in development.

The articles below explain how antibody drug conjugates work and discuss clinical trials now underway.

You can find clinical trials for patients with metastatic breast cancer using Kadcyla® in combination with other therapies here.

You can find clinical trials for patients with metastatic breast cancer using experimental antibody drug conjugates here.

 

       Subscribe

Leave a Reply